• Drug Response Assays: Viability, Killing, and Timing

  2026-09-12

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central practical implication is that in vitro drug studies should distinguish proliferative arrest from cell killing and interpret both their magnitude and timing.

• Persistent rDNA Damage and PML-Nucleolar Compartments

  2026-09-11

  The reference study identifies persistent ribosomal DNA lesions, rather than genotoxic stress alone, as a major trigger of PML-nucleolar associations. By combining chemical stress, locus-specific I-PpoI cleavage, DNA-repair perturbation, and microscopy, it connects topological stress and incomplete homologous recombination with rDNA compartmentalization and senescence.

• EZ Cap™ OVA mRNA for Immune Assays

  2026-09-11

  Use EZ Cap™ OVA mRNA as a defined antigen-expression input for carrier benchmarking, immune response immunogen studies, and translational assay development. Its Cap 1 structure and poly(A) tail support reproducible Ovalbumin mRNA delivery studies while enabling direct comparison of expression efficiency and inflammatory trade-offs.

• Bay 11-7085: From NF-κB Probe to Translation

  2026-09-10

  A translational framework for using Bay 11-7085 to connect NF-κB-dependent inflammation, proliferation, and apoptosis with endometriosis, pneumococcal meningitis, and ER stress-related neuroinflammation after subarachnoid hemorrhage.

• Sulfaphenazole-Derived Sulfonamides for TB

  2026-09-10

  Chen and colleagues optimized the sulfaphenazole scaffold to preserve antimycobacterial activity while reducing CYP2C9 inhibition, a potential source of drug–drug interactions. The study identifies compound 10d as a useful proof of concept for separating antibacterial efficacy from unwanted cytochrome P450 activity through structure-guided sulfonamide modification.

• IRG1–Itaconic Acid Restrains TBK1 Signaling

  2026-09-09

  The 2025 Cell Reports study identifies an IRG1–itaconic acid feedback axis that limits excessive TBK1-driven type I interferon production. It links metabolic remodeling to covalent modification of TBK1 at Cys605 and introduces ITA-5 and ITA-9 as preclinical chemical tools for restraining IFN-I-associated hyperinflammation.

• U0126-EtOH: Practical MEK1/2 Inhibition Workflows

  2026-09-09

  U0126-EtOH is a selective MEK1/2 inhibitor for dissecting MAPK/ERK signaling in neuronal injury, leukemia-cell death, and inflammatory models. This workflow-focused guide covers solvent handling, pathway readouts, controls, troubleshooting, and the limits of translating pathway inhibition across experimental systems.

• Gentamycin Sulfate in Resistance Research

  2026-09-08

  Gentamycin Sulfate converts ribosome-level perturbation into a practical phenotype for bacterial protein synthesis research and resistance profiling. This workflow connects gentamycin susceptibility with carbapenemase-gene detection, plasmid localization, and transmission analysis in Gram-negative isolates.

• MTT: Mechanism, Evidence, and Assay Limits

  2026-09-08

  MTT is a tetrazolium-based colorimetric cell viability assay reagent that converts cellular reductive activity into a purple formazan signal. Its result is a metabolic proxy, so careful controls and orthogonal validation are required when interpreting proliferation, cytotoxicity, or viability.

• Moxifloxacin: Designing Mechanism-to-Phenotype Assays

  2026-09-07

  Moxifloxacin is more than a DNA gyrase inhibitor: it is a useful framework for connecting target engagement with bacterial, cellular, and systemic phenotypes. This article presents an assay-centered strategy for antibiotic toxicity research, formulation control, and interpretation of metabolic responses.

• X-press Tag Peptide for RHEB Purification

  2026-09-07

  X-press Tag Peptide combines affinity capture, Anti-Xpress antibody detection, and enterokinase-based tag removal in one N-terminal design. This guide translates those features into a practical workflow for recombinant RHEB studies, including experiments inspired by the UBE2F–SAG–RHEB–mTORC1 axis.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-09-05

  A 2024 study shows that Sulforaphane reduces oxidative stress and suppresses NLRP3 inflammasome-associated inflammation in DSS-induced mouse colitis. Its combination of in vivo disease modeling and RAW264.7 cell experiments supports a redox-sensitive mechanism, while also defining important limits for translation to human ulcerative colitis.

• ABT-263 Workflow for Mitochondrial Apoptosis

  2026-09-04

  Build a more informative ABT-263 and Navitoclax workflow by pairing apoptosis measurements with mitochondrial state, Bcl-2-family dependency, and resistance analysis. This practical guide covers reagent handling, dose-response design, pediatric acute lymphoblastic leukemia model considerations, and troubleshooting for reproducible cancer biology studies.

• Resazurin Cell Viability Assay Kit Guide

  2026-09-04

  Learn how the Resazurin Cell Viability Assay Kit can complement mechanistic bone research by separating treatment-related cytotoxicity from altered osteoblast metabolism. This guide translates recent PORCN-inhibition findings into practical, high-sensitivity cell viability assay decisions.

• Talabostat Mesylate: FAP Activity to Tumor Biology

  2026-09-03

  Talabostat mesylate, also known as PT-100, connects DPP4/FAP enzymology with tumor-microenvironment research. This article explains how to distinguish protease activity from protein abundance and how a FAP-sensitive nanoparticle study can improve assay design and interpretation.

8579 records 1/572 page Next 12345 下5页 Last page